Correction of the PMP22 expression level reverses the demyelination phenotype in a transgenic animal model [64], and the relevance of reducing PMP22 expression has been acknowledged as one potential therapeutic approach for CMT1A [65]. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.